

Steven K Grinspoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5428962/publications.pdf>

Version: 2024-02-01

136
papers

9,955
citations

41344

49
h-index

34986

98
g-index

136
all docs

136
docs citations

136
times ranked

7751
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	4.0	8
2	Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab175.	0.2	1
3	Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. <i>Clinical Infectious Diseases</i> , 2022, 75, 1154-1163.	5.8	4
4	Approach to the Patient With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1714-1726.	3.6	10
5	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 349-359.	2.1	4
6	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2022, 75, 1324-1333.	5.8	8
7	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. <i>Journal of Infectious Diseases</i> , 2022, 226, 1809-1822.	4.0	11
8	Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 2087-2094.	5.8	15
9	Reply to Maurice and Lemoine. <i>Clinical Infectious Diseases</i> , 2021, 72, 909-909.	5.8	0
10	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e520-e533.	3.6	43
11	Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3398-3412.	3.6	3
12	Tesamorelin improves fat quality independent of changes in fat quantity. <i>Aids</i> , 2021, 35, 1395-1402.	2.2	3
13	Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. <i>Scientific Reports</i> , 2021, 11, 10485.	3.3	6
14	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. <i>JAMA Network Open</i> , 2021, 4, e2114923.	5.9	38
15	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	5.8	19
16	A neurobiological link between transportation noise exposure and metabolic disease in humans. <i>Psychoneuroendocrinology</i> , 2021, 131, 105331.	2.7	10
17	Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. <i>JCI Insight</i> , 2021, 6, .	5.0	10
18	A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. <i>Viruses</i> , 2021, 13, 2135.	3.3	1

#	ARTICLE	IF	CITATIONS
19	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.9	19
20	Individual coronary plaque changes on serial CT angiography: Within-patient heterogeneity, natural history, and statin effects in HIV. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 144-148.	1.3	9
21	Association of In Utero HIV Exposure With Obesity and Reactive Airway Disease in HIV-Negative Adolescents and Young Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 126-134.	2.1	8
22	Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. <i>Journal of Infectious Diseases</i> , 2020, 222, S1-S7.	4.0	28
23	An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 222, S41-S51.	4.0	1
24	Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa459.	0.9	6
25	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	4.0	8
26	Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S20-S30.	4.0	16
27	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , 2020, 21, 11-23.	1.1	5
28	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. <i>Journal of Infectious Diseases</i> , 2020, 222, S31-S40.	4.0	4
29	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	4.0	17
30	Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. <i>Journal of Infectious Diseases</i> , 2020, 222, S52-S62.	4.0	22
31	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. <i>Obesity</i> , 2020, 28, 749-755.	3.0	9
32	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. <i>Journal of Infectious Diseases</i> , 2020, 222, 929-939.	4.0	16
33	Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. <i>JCI Insight</i> , 2020, 5, .	5.0	13
34	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1762-1775.	2.4	20
35	Serum Lipocalin 2 (Neutrophil Gelatinase-Associated Lipocalin) in Relation to Biomarkers of Inflammation and Cardiac Stretch During Activation of the Renin-Angiotensin-Aldosterone System in Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2019, 220, 1420-1424.	4.0	6
36	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. <i>Lancet HIV</i> , 2019, 6, e821-e830.	4.7	50

#	ARTICLE	IF	CITATIONS
37	Myocardial Dysfunction With Contemporary Management of HIV. <i>JACC: Heart Failure</i> , 2019, 7, 109-111.	4.1	3
38	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e98-e124.	1.6	376
39	Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 420-431.	4.0	64
40	Comparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIV. <i>Nutrition and Diabetes</i> , 2019, 9, 6.	3.2	13
41	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	2.7	43
42	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	2.7	99
43	Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1029-1038.	3.6	15
44	Amygdalar activity predicts future incident diabetes independently of adiposity. <i>Psychoneuroendocrinology</i> , 2019, 100, 32-40.	2.7	24
45	SAT-256 Obesity and Reactive Airway Disease Are Increased Among HIV-Exposed Uninfected Adolescents. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
46	Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2376-2384.	3.6	20
47	Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. <i>Circulation</i> , 2018, 137, 2203-2214.	1.6	151
48	Novel mediators of statin effects on plaque in HIV. <i>Aids</i> , 2018, 32, 867-876.	2.2	9
49	Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 105-110.	2.1	14
50	Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy326.	0.9	7
51	Significant Association of Aldosterone and Liver Fat Among HIV-Infected Individuals With Metabolic Dysregulation. <i>Journal of the Endocrine Society</i> , 2018, 2, 1147-1157.	0.2	8
52	Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4176-4186.	3.6	23
53	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. <i>EBioMedicine</i> , 2018, 35, 58-66.	6.1	16
54	Excessive Adiposity and Metabolic Dysfunction Relate to Reduced Natriuretic Peptide During RAAS Activation in HIV. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1558-1565.	3.6	10

#	ARTICLE	IF	CITATIONS
55	Benefits and Risks of Statin Therapy in the HIV-Infected Population. <i>Current Infectious Disease Reports</i> , 2018, 20, 20.	3.0	25
56	NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS. <i>Transactions of the American Clinical and Climatological Association</i> , 2018, 129, 140-154.	0.5	8
57	Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. <i>HIV Clinical Trials</i> , 2017, 18, 83-91.	2.0	14
58	Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. <i>Aids</i> , 2017, 31, 797-806.	2.2	74
59	Acute hyperinsulinemia effects on systemic markers of immune activation in HIV. <i>Aids</i> , 2017, 31, 1771-1773.	2.2	3
60	Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	20
61	Unraveling Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1403-1412.	2.8	59
62	Epidemiology of ischemic heart disease in HIV. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 540-547.	3.8	35
63	Differential relationships of hepatic and epicardial fat to body composition in HIV. <i>Physiological Reports</i> , 2017, 5, e13386.	1.7	9
64	Cardiovascular Disease Imaging in HIV. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	4
65	Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. <i>Aids</i> , 2017, 31, 2253-2259.	2.2	9
66	Inflammation, immune activation, and cardiovascular disease in HIV. <i>Aids</i> , 2016, 30, 1495-1509.	2.2	152
67	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2016, 1, 474.	6.1	66
68	Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004043.	2.6	50
69	Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices During HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1336-1340.	4.0	15
70	Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw062.	0.9	10
71	Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. <i>Aids</i> , 2016, 30, 583-590.	2.2	45
72	Dysfunctional Subcutaneous Fat With Reduced Dicer and Brown Adipose Tissue Gene Expression in HIV-Infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1225-1234.	3.6	39

#	ARTICLE	IF	CITATIONS
73	Pathophysiology and management of cardiovascular disease in patients with HIV. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 598-610.	11.4	66
74	Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1123-1133.	3.6	19
75	<i>Endocrinology of HIV/AIDS.</i> , 2016, , 1776-1798.		1
76	Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu117.	0.9	54
77	Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. <i>Aids</i> , 2015, 29, 443-452.	2.2	60
78	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2015, 2, e52-e63.	4.7	188
79	Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. <i>Clinical Endocrinology</i> , 2015, 82, 678-685.	2.4	24
80	Elevated Levels of Monocyte Activation Markers Are Associated With Subclinical Atherosclerosis in Men With and Those Without HIV Infection. <i>Journal of Infectious Diseases</i> , 2015, 211, 1219-1228.	4.0	159
81	RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2873-2882.	3.6	75
82	The past 10 years—new hormones, new functions, new endocrine organs. <i>Nature Reviews Endocrinology</i> , 2015, 11, 681-686.	9.6	12
83	Abstract 15567: Increased Visceral Fat Volume is Associated With Aortic Inflammation and Cardiovascular Events. <i>Circulation</i> , 2015, 132, .	1.6	0
84	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. <i>Topics in Antiviral Medicine</i> , 2015, 23, 146-9.	0.1	70
85	Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 164-171.	2.1	66
86	Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. <i>Neurology</i> , 2014, 83, 1705-1711.	1.1	51
87	Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 380.	7.4	70
88	Epicardial adipose tissue and atherogenesis. <i>Aids</i> , 2014, 28, 1679-1681.	2.2	2
89	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. <i>Aids</i> , 2014, 28, 2061-2070.	2.2	65
90	Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women. <i>Menopause</i> , 2014, 21, 403-409.	2.0	52

#	ARTICLE	IF	CITATIONS
91	High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity Is Improved by Treatment With Antiretroviral Therapy in Acute Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu108.	0.9	23
92	Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu076.	0.9	29
93	Risk of coronary heart disease in patients with HIV infection. <i>Nature Reviews Cardiology</i> , 2014, 11, 728-741.	13.7	90
94	Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity. <i>Growth Hormone and IGF Research</i> , 2014, 24, 10-15.	1.1	14
95	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. <i>Antiviral Therapy</i> , 2014, 19, 805-811.	1.0	16
96	Measurement of Arterial Activity on Routine FDG PET/CT Images Improves Prediction of Risk of Future CV Events. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 1250-1259.	5.3	273
97	Effects of aging and smoking on carotid intima-media thickness in HIV-infection. <i>Aids</i> , 2013, 27, 49-57.	2.2	26
98	Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. <i>Aids</i> , 2013, 27, 1263-1272.	2.2	115
99	Noncalcified Coronary Atherosclerotic Plaque and Immune Activation in HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2013, 208, 1737-1746.	4.0	185
100	Deiodinase 2 Expression Is Increased in Dorsocervical Fat of Patients with HIV-Associated Lipohypertrophy Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E602-E607.	3.6	29
101	Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Teseamorelin. <i>Clinical Infectious Diseases</i> , 2012, 54, 1642-1651.	5.8	25
102	Arterial Inflammation in Patients With HIV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 379.	7.4	411
103	Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. <i>Aids</i> , 2012, 26, 587-597.	2.2	73
104	Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. <i>Aids</i> , 2012, 26, 2409-2412.	2.2	177
105	Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 150-158.	3.6	43
106	HIV-associated dyslipidemia: the Heart Positive study. <i>Nature Reviews Endocrinology</i> , 2011, 7, 443-444.	9.6	0
107	Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 1227-1236.	4.0	374
108	Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. <i>Aids</i> , 2010, 24, 243-253.	2.2	287

#	ARTICLE	IF	CITATIONS
109	Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. <i>Aids</i> , 2010, 24, 2127-2130.	2.2	51
110	Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4291-4304.	3.6	77
111	Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 615-619.	2.1	148
112	Increased aldosterone among HIV-infected women with visceral fat accumulation. <i>Aids</i> , 2009, 23, 2366-2370.	2.2	17
113	Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 268-273.	2.1	310
114	Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 509.	7.4	80
115	The Effects of Central Adiposity on Growth Hormone (GH) Response to GH-Releasing Hormone-Arginine Stimulation Testing in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4254-4260.	3.6	105
116	Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 174-184.	2.1	56
117	Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2506-2512.	3.6	1,404
118	Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. <i>New England Journal of Medicine</i> , 2007, 357, 2359-2370.	27.0	168
119	Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. <i>The American Journal of Medicine: Supplement</i> , 2005, 118, 23-28.	1.6	49
120	Rosiglitazone for Treatment of HIV Lipodystrophy. <i>Annals of Internal Medicine</i> , 2004, 141, 739.	3.9	0
121	Effects of Estrogen and Recombinant Human Insulin-Like Growth Factor-I on Ghrelin Secretion in Severe Undernutrition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3988-3993.	3.6	42
122	Metabolic Effects of Rosiglitazone in HIV Lipodystrophy. <i>Annals of Internal Medicine</i> , 2004, 140, 786.	3.9	195
123	Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution. <i>Clinical Infectious Diseases</i> , 2003, 36, 909-916.	5.8	120
124	Mechanisms and Strategies for Insulin Resistance in Acquired Immune Deficiency Syndrome. <i>Clinical Infectious Diseases</i> , 2003, 37, S85-S90.	5.8	54
125	Weight Loss and Wasting in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2003, 36, S69-S78.	5.8	147
126	Sustained Benefits of Metformin Therapy on Markers of Cardiovascular Risk in Human Immunodeficiency Virus-Infected Patients with Fat Redistribution and Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4611-4615.	3.6	88

#	ARTICLE	IF	CITATIONS
127	Effects of Recombinant Human IGF-I and Oral Contraceptive Administration on Bone Density in Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2883-2891.	3.6	316
128	Testosterone and Resistance Training in AIDS. <i>Annals of Internal Medicine</i> , 2001, 135, 65.	3.9	1
129	Regional Osteoporosis in Anorexia Nervosa. <i>Annals of Internal Medicine</i> , 2001, 135, 844.	3.9	4
130	Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy. <i>Clinical Infectious Diseases</i> , 2001, 32, 130-139.	5.8	639
131	Mechanisms of Androgen Deficiency in Human Immunodeficiency Virus-Infected Women with the Wasting Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4120-4126.	3.6	62
132	Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Related Lipodystrophy1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 504-510.	3.6	145
133	Mechanisms of Androgen Deficiency in Human Immunodeficiency Virus-Infected Women with the Wasting Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4120-4126.	3.6	12
134	Assessment of macronutrient and micronutrient intake in women with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2000, 28, 284-292.	4.0	168
135	Metformin in the Treatment of HIV Lipodystrophy Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 472-7.	7.4	289
136	AIDS: Endocrinologic and Metabolic Considerations. <i>Annals of Medicine</i> , 1994, 26, 321-323.	3.8	1